Benzinga··Eva MathewNiagen Bioscience Doubles Profits, Eyes M&A as Stock Trades Well Below Peak
Niagen Bioscience doubled annual profits with $129.4M in sales and 30% revenue growth. CEO signals acquisition hunt and GLP-1-style expansion despite modest 2026 guidance.
NAGEacquisitionsNAD+ supplements